Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Cross-reactive antibody responses against SARS-CoV-2 and seasonal common cold coronaviruses

Shelley Klompus, Sigal Leviatan, Thomas Vogl, Iris N. Kalka, Anastasia Godneva, Eilat Shinar, Adina Weinberger, Eran Segal
doi: https://doi.org/10.1101/2020.09.01.20182220
Shelley Klompus
1Department of Computer Science and Applied Mathematics, Weizmann Institute of Science
2Department of Molecular Cell Biology, Weizmann Institute of Science
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sigal Leviatan
1Department of Computer Science and Applied Mathematics, Weizmann Institute of Science
2Department of Molecular Cell Biology, Weizmann Institute of Science
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Vogl
1Department of Computer Science and Applied Mathematics, Weizmann Institute of Science
2Department of Molecular Cell Biology, Weizmann Institute of Science
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: thomas.vogl@weizmann.ac.il eran.segal@weizmann.ac.il
Iris N. Kalka
1Department of Computer Science and Applied Mathematics, Weizmann Institute of Science
2Department of Molecular Cell Biology, Weizmann Institute of Science
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anastasia Godneva
1Department of Computer Science and Applied Mathematics, Weizmann Institute of Science
2Department of Molecular Cell Biology, Weizmann Institute of Science
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eilat Shinar
3Magen David Adom Blood Services, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adina Weinberger
1Department of Computer Science and Applied Mathematics, Weizmann Institute of Science
2Department of Molecular Cell Biology, Weizmann Institute of Science
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eran Segal
1Department of Computer Science and Applied Mathematics, Weizmann Institute of Science
2Department of Molecular Cell Biology, Weizmann Institute of Science
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: thomas.vogl@weizmann.ac.il eran.segal@weizmann.ac.il
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Beyond SARS-CoV-2, six more coronaviruses infect humans (hCoVs), four of which cause only mild symptoms (seasonal/common cold hCoVs) 12. Previous exposures to seasonal hCoVs may elicit immunological memory that could benefit the course of SARS-CoV-2 infections 3. While cross-reactive T cells epitopes of SARS-CoV-2 and seasonal hCoVs have been reported in individuals unexposed to SARS-CoV-2 4-6, potential antibody-based cross-reactivity is incompletely understood.

Here, we have probed for high resolution antibody binding against all hCoVs represented as 1,539 peptides with a phage-displayed 7 antigen library. We detected broad serum antibody responses against peptides of seasonal hCoVs in up to 75% of individuals. Recovered COVID-19 patients exhibited distinct antibody repertoires targeting variable SARS-CoV-2 epitopes, and could be accurately classified from unexposed individuals (AUC=0.96). Up to 50% of recovered patients also mounted antibody responses against unique epitopes of seasonal hCoV-OC43, that were not detectable in unexposed individuals.

These results indicate substantial interindividual variability and antibody cross-reactivity between hCoVs from the direction of SARS-CoV-2 infections towards seasonal hCoVs. Our accurate high throughput assay allows profiling preexisting antibody responses against seasonal hCoVs cost-effectively and could inform on their protective nature against SARS-CoV-2.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

E.S.s COVID-19 research is supported by the Seerave Foundation. T.V. is supported by an Erwin Schroedinger fellowship (J 4256) from the Austrian Science Fund (FWF).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Research with the COVID-19 serum samples has been approved by the Weizmann Institute of Science s institutional review board (#1030-4), and by the Tel Aviv Sourasky Medical Center for the samples of unexposed individuals (#0658-12-TLV).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • References updated and additional supporting information added.

Data Availability

The majority of data generated or analyzed during this study are included in this published article (and its supplementary information files). Additional datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 09, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Cross-reactive antibody responses against SARS-CoV-2 and seasonal common cold coronaviruses
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Cross-reactive antibody responses against SARS-CoV-2 and seasonal common cold coronaviruses
Shelley Klompus, Sigal Leviatan, Thomas Vogl, Iris N. Kalka, Anastasia Godneva, Eilat Shinar, Adina Weinberger, Eran Segal
medRxiv 2020.09.01.20182220; doi: https://doi.org/10.1101/2020.09.01.20182220
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Cross-reactive antibody responses against SARS-CoV-2 and seasonal common cold coronaviruses
Shelley Klompus, Sigal Leviatan, Thomas Vogl, Iris N. Kalka, Anastasia Godneva, Eilat Shinar, Adina Weinberger, Eran Segal
medRxiv 2020.09.01.20182220; doi: https://doi.org/10.1101/2020.09.01.20182220

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (166)
  • Anesthesia (49)
  • Cardiovascular Medicine (447)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (188)
  • Epidemiology (5195)
  • Forensic Medicine (3)
  • Gastroenterology (192)
  • Genetic and Genomic Medicine (746)
  • Geriatric Medicine (76)
  • Health Economics (210)
  • Health Informatics (689)
  • Health Policy (350)
  • Health Systems and Quality Improvement (221)
  • Hematology (98)
  • HIV/AIDS (161)
  • Infectious Diseases (except HIV/AIDS) (5787)
  • Intensive Care and Critical Care Medicine (353)
  • Medical Education (101)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (754)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (140)
  • Occupational and Environmental Health (230)
  • Oncology (473)
  • Ophthalmology (149)
  • Orthopedics (37)
  • Otolaryngology (93)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (138)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (135)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (851)
  • Public and Global Health (1982)
  • Radiology and Imaging (340)
  • Rehabilitation Medicine and Physical Therapy (154)
  • Respiratory Medicine (282)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (74)
  • Surgery (107)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)